TrialCancer immunology, immunotherapy : CII2016

Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.

Stephanie Du Four et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.